中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

胆汁酸在肝硬化心肌病中的作用

梁世洋 林强 宋俊良 王景杰

引用本文:
Citation:

胆汁酸在肝硬化心肌病中的作用

DOI: 10.3969/j.issn.1001-5256.2022.10.035
基金项目: 

国家自然科学基金面上项目 (81770534)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:梁世洋负责课题选题,搜集分析资料,撰写论文; 林强、宋俊良负责课题选题,资料搜集; 王景杰负责拟定写作思路,指导撰写文章并最终定稿。
详细信息
    通信作者:

    王景杰,jingjiefmmu@163.com

Role of bile acids in cirrhosis-related cardiomyopathy

Research funding: 

National Natural Science Foundation of China (General Project) (81770534)

More Information
  • 摘要: 肝硬化心肌病(CCM)是肝硬化伴有的一种常见且容易被忽视的并发症, 其发病率较高, 且对肝移植和经颈静脉肝内门体分流术的预后有明显影响,近年来引起研究人员的高度关注。肝硬化患者常伴有血清总胆汁酸水平升高和胆汁酸组成改变, 而高浓度胆汁酸具有心脏毒性。基于文献证据,本文总结了肝硬化患者胆汁酸代谢的改变、胆汁酸对心脏功能的影响及熊去氧胆酸为CCM的潜在治疗药物3个方面内容,旨在为CCM的预防和治疗提供新思路。

     

  • [1] IZZY M, VANWAGNER LB, LIN G, et al. Redefining cirrhotic cardiomyopathy for the modern era[J]. Hepatology, 2020, 71(1): 334-345. DOI: 10.1002/hep.30875.
    [2] CHAHAL D, LIU H, SHAMATUTU C, et al. Review article: comprehensive analysis of cirrhotic cardiomyopathy[J]. Aliment Pharmacol Ther, 2021, 53(9): 985-998. DOI: 10.1111/apt.16305.
    [3] VANWAGNER LB, SERPER M, KANG R, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample[J]. Am J Transplant, 2016, 16(9): 2684-2694. DOI: 10.1111/ajt.13779.
    [4] BILLEY C, BILLET S, ROBIC MA, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the toulouse algorithm[J]. Hepatology, 2019, 70(6): 1928-1941. DOI: 10.1002/hep.30934.
    [5] RIMAL B, PATTERSON AD. Role of bile acids and gut bacteria in healthy ageing of centenarians[J]. Nature, 2021, 599(7885): 380-381. DOI: 10.1038/d41586-021-02196-0.
    [6] DESAI MS, MATHUR B, EBLIMIT Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart[J]. Hepatology, 2017, 65(1): 189-201. DOI: 10.1002/hep.28890.
    [7] DESAI MS, SHABIER Z, TAYLOR M, et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis[J]. Hepatology, 2010, 51(6): 2097-2107. DOI: 10.1002/hep.23585.
    [8] GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/s0140-6736(21)01374-x.
    [9] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of cholestasis liver diseases(2015)[J]. J Clin Hepatol, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.
    [10] GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
    [11] CHEN W, WEI Y, XIONG A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2.
    [12] TROTTIER J, BIA EK A, CARON P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study[J]. Dig Liver Dis, 2012, 44(4): 303-310. DOI: 10.1016/j.dld.2011.10.025.
    [13] YAN LT, LI JF, DUAN ZP, et al. Relationship between bile acid metabolism and chronic non -cholestatic liver disease[J]. Chin J Hepatol, 2018, 26 (2): 151-154. DOI: 10.3760/cma.j.issn.1007-3418.2018.02.016.

    闫力婷, 李俊烽, 段钟平, 等. 胆汁酸代谢与慢性非胆汁淤积性肝脏疾病的关系[J]. 中华肝脏病杂志, 2018, 26(2): 151-154. DOI: 10.3760/cma.j.issn.1007-3418.2018.02.016.
    [14] YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
    [15] YAN H, PENG B, LIU Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol, 2014, 88(6): 3273-3284. DOI: 10.1128/JVI.03478-13.
    [16] OEHLER N, VOLZ T, BHADRA OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493. DOI: 10.1002/hep.27159.
    [17] MOUZANNAR K, FUSIL F, LACOMBE B, et al. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo[J]. FASEB J, 2019, 33(2): 2472-2483. DOI: 10.1096/fj.201801181R.
    [18] YAN LT, WANG LL, YAO J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection[J]. Medicine (Baltimore), 2020, 99(8): e19248. DOI: 10.1097/MD.0000000000019248.
    [19] LI JF, YAN LT, YANG YT, et al. Serum total bile acid is closely related to the significant liver injury in patients with non-cholestatic chronic hepatitis B virus infection: a cross-sectional study[J]. Clin Lab, 2020, 66(8): 1591-1600. DOI: 10.7754/Clin.Lab.2020.191258.
    [20] SANG C, WANG X, ZHOU K, et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease[J]. J Proteome Res, 2021, 20(5): 2340-2351. DOI: 10.1021/acs.jproteome.0c00852.
    [21] POWELL EE, WONG VW-S, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [22] NIMER N, CHOUCAIR I, WANG Z, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression[J]. Metabolism, 2021, 116: 154457. DOI: 10.1016/j.metabol.2020.154457.
    [23] XIAO P, BA TT, DING MM, et al. Advances in clinical research on liver disease during pregnancy[J]. J Clin Hepatol, 2021, 37(5): 1229-1232. DOI: 10.3969/j.issn.1001-5256.2021.05.054.

    肖鹏, 巴桃桃, 丁梦梦, 等. 妊娠期肝病临床研究进展[J]. 临床肝胆病杂志, 2021, 37(5): 1229-1232. DOI: 10.3969/j.issn.1001-5256.2021.05.054.
    [24] WILLIAMSON C, GORELIK J, EATON BM, et al. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis[J]. Clin Sci (Lond), 2001, 100(4): 363-369. DOI: 10.1042/CS20000164
    [25] VASAVAN T, DEEPAK S, JAYAWARDANE IA, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations[J]. J Hepatol, 2021, 74(5): 1087-1096. DOI: 10.1016/j.jhep.2020.11.038.
    [26] KEMPLER P, VÁRADI A, KÁDAR E, et al. Autonomic and peripheral neuropathy in primary biliary cirrhosis: evidence of small sensory fibre damage and prolongation of the QT interval[J]. J Hepatol, 1994, 21(6): 1150-1151. DOI: 10.1016/s0168-8278(05)80640-3.
    [27] CZUL F, PEYTON A, LEVY C. Primary biliary cirrhosis: therapeutic advances[J]. Clin Liver Dis, 2013, 17(2): 229-242. DOI: 10.1016/j.cld.2012.12.003.
    [28] NAM SW, LIU H, WONG JZ, et al. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct- ligated mice[J]. Clin Sci (Lond), 2014, 127(8): 519-526. DOI: 10.1042/CS20130642.
    [29] VOIOSU AM, WIESE S, VOIOSU TA, et al. Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis[J]. Eur J Gastroenterol Hepatol, 2018, 30(4): 392-397. DOI: 10.1097/MEG.0000000000001043.
    [30] DESAI MS, EBLIMIT Z, THEVANANTHER S, et al. Cardiomyopathy reverses with recovery of liver injury, cholestasis and cholanemia in mouse model of biliary fibrosis[J]. Liver Int, 2015, 35(4): 1464-1477. DOI: 10.1111/liv.12438.
    [31] FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82: 101094. DOI: 10.1016/j.plipres.2021.101094.
    [32] PU J, YUAN A, SHAN P, et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury[J]. Eur Heart J, 2013, 34(24): 1834-1845. DOI: 10.1093/eurheartj/ehs011.
    [33] WANG J, ZHANG J, LIN X, et al. DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction[J]. J Mol Cell Cardiol, 2021, 151: 3-14. DOI: 10.1016/j.yjmcc.2020.10.014.
    [34] SHAH RA, KOWDLEY KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315. DOI: 10.1016/S2468-1253(19)30343-7.
    [35] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 50-61. DOI: 10.3760/cma.j.cn112138-20211109-00786.

    中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 50-61. DOI: 10.3760/cma.j.cn112138-20211109-00786.
    [36] OVADIA C, SAJOUS J, SEED PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 547-558. DOI: 10.1016/S2468-1253(21)00074-1.
    [37] HANAFI NI, MOHAMED AS, SHEIKH ABDUL KADIR SH, et al. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart[J]. Biomolecules, 2018, 8(4): 159. DOI: 10.3390/biom8040159.
    [38] MOUSA OY, JURAN BD, MCCAULEY BM, et al. Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation[J]. Hepatology, 2021, 74(1): 281-295. DOI: 10.1002/hep.31652.
  • 加载中
计量
  • 文章访问数:  382
  • HTML全文浏览量:  107
  • PDF下载量:  65
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-08
  • 录用日期:  2022-04-12
  • 出版日期:  2022-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回